Association Of The Tauopathy Gwas Loci With Alzheimer'S Disease In China

Qiu-Yan Liu,Jin-Tai Yu,Lan Tan
DOI: https://doi.org/10.1212/wnl.80.7_supplement.p04.220
IF: 9.9
2013-01-01
Neurology
Abstract:OBJECTIVE: To explore the relationship of Alzheimer9s disease (AD) with selected single-nucleotide polymorphisms (SNPs) from the tauopathy progressive supranuclear palsy (PSP) genome-wide association study (GWAS) in a large Han Chinese population. BACKGROUND: Both AD and PSP are a class of neurodegenerative diseases with prominent tau neuropathology. A recent PSP GWAS identified several common genetic variations within the STX6 , MOBP , MAPT and EIF2AK3 genes contributing to risk for tauopathies. The expression levels and functional features of these genes exclusively supported their associations with PSP. DESIGN/METHODS: We recruited 1,592 unrelated Northern Han Chinese individuals comprising 796 patients with a clinical diagnosis of LOAD and 796 healthy age- and sex-matched controls. The selected SNPs in STX6, MOBP, EIF2AK3 and MAPT were genotyped with the method of polymerase chain reaction–ligase detection reaction (LDR) on an ABI Prism 377 Sequence Detection System. RESULTS: Rs242557 at the MAPT locus was associated with late-onset AD (LOAD) (OR = 1.175, P = 0.026), which appeared to be stronger for LOAD patients with apolipoprotein E ( APOE ) e4 allele (OR = 1.510). And this positive association was not changed after adjusting for age, gender and the APOE e4-carrier status (additive model: OR = 1.163, P = 0.036; dominant model: OR = 1.315, P = 0.010). Rs1768208 in MOBP and rs7571971 in EIF2AK3 showed association only in the APOE e4 positive subjects, and these did not appear to be independent of APOE . As for rs1411478 in STX6 , we did not explore any association with LOAD. CONCLUSIONS: Our exploratory analysis mainly suggests an association of MAPT with LOAD, especially in APOE e4 carriers. Genotypes at MOBP and EIF2AK3 confer risk predominantly in APOE e4-positive subjects, with indications of an interaction between APOE and MOBP or EIF2AK3 on AD risk. Supported by: Grants from the National Natural Science Foundation of China (81000544, 81171209). Disclosure: Dr. Liu has nothing to disclose. Dr. Yu has nothing to disclose. Dr. Tan has nothing to disclose.
What problem does this paper attempt to address?